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Abstract  
Introduction: Tuberculosis (TB) is currently causing more deaths than Human Immunodeficiency Virus (HIV) globally. Ghana as one of the 30 high 
burden TB/HIV countries has a high annual TB case-fatality rate of 10%. The study sought to assess the effect of HIV infection on TB treatment 
outcomes and assess the time to mortality after treatment onset. Methods: we conducted a review of treatment files of TB patients who were 
treated from January 2013 to December 2015 in two urban hospitals in the Accra Metropolis. Modified Poisson regression analysis was used to 
measure the association between HIV infection and TB treatment outcomes. Kaplan-Meier survival estimates were used to plot survival curves. 
Results: seventy-seven percent (83/107) of HIV infected individuals had successful treatment, compared to 91.2% (382/419) treatment success 
among HIV non-infected individuals. The proportion of HIV-positive individuals who died was 21.5% (23/107) whilst that of HIV-negative individuals 
was 5.5% (23/419). Being HIV-positive increased the risk of adverse outcome relative to successful outcome by a factor of 2.89(95% CI 1.76-4.74). 
The total number of deaths recorded within the treatment period was 46; of which 29(63%) occurred within the first two months of TB treatment. 
The highest mortality rate observed was among HIV infected persons (38.6/1000 person months). Of the 107 TB/HIV co-infected patients, 4(3.7%) 
initiated ART during TB treatment. Conclusion: the uptake of ART in co-infected individuals in this study was very low. Measures should be put in 
place to improve ART coverage among persons with TB/HIV co-infection to help reduce mortality. 
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Antiretroviral therapy (ART) use in areas endemic with tuberculosis 
(TB) is highly beneficial but HIV treatment coverage remains 
suboptimal. Early initiation of ART improves survival of people living 
with human immunodeficiency virus (HIV), reduces the incidence of 
TB and delays the progression of HIV [1, 2]. In patients with TB/HIV 
coinfection, concurrent ART during TB treatment is also associated 
with improved survival among patients [3, 4]. ART suppresses viral 
replication; transforming HIV infection from a highly fatal to a chronic 
disease that can be managed with a favorable prognosis [5]. There 
has been more than a two-fold increase in the number of people 
receiving ART since 2010 in the world's most affected regions - 
Eastern and Southern Africa. This has made a huge contribution to 
the reduction in acquired immune deficiency syndrome (AIDS)-related 
deaths worldwide - from 1.4 million in 2010 to 940,000 in 2017 [6]. 
It is estimated that about 54 million deaths worldwide have been 
prevented by TB diagnosis and treatment between the year 2000 and 
2017 [7]. Yet the TB/HIV syndemic continues to claim millions of lives 
each year [8]. Tuberculosis accelerates the progression of HIV 
infection to AIDS if left untreated [9]. Deaths from TB have fallen by 
42% from the year 2000 to 2017, however, TB is still one of the 
leading causes of mortality in the world; now causing more deaths 
than HIV [7]. In 2015, about 75% of TB/HIV deaths worldwide 
occurred in Sub Saharan Africa, with case fatality rates varying from 
under 5% to over 20% among countries in the region [8]. 
Tuberculosis mortality rate in 2015 was 47% lower than in 1990 
globally. The target was to reduce the mortality rate by 50% by the 
year 2015, which was achieved by the WHO Region of the Americas, 
South-East Asia Region, Western Pacific, Eastern Mediterranean and 
11 of the high TB burden countries [10]. Latest reports suggest that 
the WHO African Region now has one of the fastest rates of 
reductions in mortality (4% per year, since 2013 to 2015); second to 
the WHO European Region with 5% per year in the same five 
years [7]. 
  
The post 2015 agenda of the WHO is to end TB by the year 2035. 
One of the End TB Strategy targets is to eventually decrease the 
number of TB deaths by 95% by the year 2035 compared to 2015 [8]. 
Ghana is recognized as one of the 30 countries in the world with a 
high burden of TB/HIV co-infection; estimated at 36 per 100,000 
population annually [8]. Annual case-fatality rates in Ghana have 
been consistently about 10% over the past few years whilst annual 
rates of lost-to-follow up (LTFU) and treatment failure have remained 
at about 3% and 2% respectively [11]. Interventions are necessary 
to reduce deaths during TB treatment in order for the country to 
achieve the targets set in the End TB Strategy by 2035. A study 
among 1797 patients found no significant difference between the 
outcomes of treatment between HIV infected and non-infected 
patients whilst cure rates in TB/HIV co-infected patients were found 
to be significantly reduced in one retrospective cohort 
analysis [12, 13]. Again, the odds of death was seven times higher 
among HIV-infected TB patients in an Ethiopian study [14]. A Nigerian 
study among 1424 TB patients reported a proportionate mortality of 
50.6% and a mortality rate of 37.6 per 100 person months all in the 
first week of TB treatment onset [15]. In another study majority of 
the deaths occurred in the intensive phase however, the risk of death 
was significantly increased among persons who were TB/HIV co-
infected in the continuation phase of TB treatment [16]. Even though 
studies have reported that HIV infection increases the risk of adverse 
outcome, there are some knowledge gaps with respect to death 
among co-infected patients in Ghana. Questions on the timing of 
death and the influential factors still need to be answered as this may 
be important for designing strategies to reduce mortality rated in 
TB/HIV co-infected patients. The objectives of the study were to 
assess the effect of HIV infection on TB treatment outcomes and the 





Study design: we conducted a review of treatment files and 
registers of TB patients who were treated from 1stJanuary 2013 to 
31st December 2015. A data extraction form was used to collect 
relevant information from TB treatment cards and registers. Study 
participants joined the cohort on the day TB treatment was initiated 
until the day any of the treatment outcomes was achieved. 
  
Setting: the study was conducted in two primary health care 
facilities located in the Accra Metropolis in the Greater Accra Region 
of Ghana. The Greater Accra Region is known to have one of the 
highest annual TB case notification rates in the country [17] and the 
Accra Metropolis is the most densely populated part of the Greater 
Accra Region with a population of about 1,665,086 in 2010 [17, 18]. 
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Inclusion criteria: all TB patients 15 years and above who were 
given TB treatment at any time from 1stJanuary 2013 to 
31st December 2015. 
  
Exclusion criteria: patients with multi-drug resistant TB (MDR-TB). 
Patients who were transferred to other clinics to continue treatment. 
  
Selection of study participants: all eligible participants were 




Outcome variables: 1) TB treatment outcomes: Successful 
outcome (cured, treatment completed), adverse outcome (treatment 
failure, died and lost-to-follow up). 2) Time period between TB 
treatment initiation and death. 
  
Exposure variable: HIV status-HIV infected or HIV non-infected. 
  
Potential confounders/predictors: age, sex, TB type-smear 
positive pulmonary TB, smear negative pulmonary TB and extra 
pulmonary TB. History of previous TB treatment-new patients, relapse 
patients, treatment after failure patients and treatment after lost-to-
follow up patients. Treatment-cotrimoxazole preventive therapy, anti-




Definition of terms: the following are standard World Health 
Organisation (WHO) definitions for the various TB treatment 
outcomes [19]. 
  
Cured: a pulmonary TB patient with bacteriologically confirmed TB 
at the beginning of treatment who was smear or culture negative in 
the last month of treatment and on at least one previous occasion. 
  
Treatment completed: a TB patient who completed treatment 
without evidence of failure but with no record to show that sputum 
smear or culture results in the last month of treatment and on at least 
one previous occasion were negative either because tests were not 
done or because results are unavailable. 
  
Successful treatment outcome (treatment success): the sum 
of cured and treatment completed. 
  
Treatment failure: a TB patient whose sputum smear or culture is 
positive at month 5 or later during treatment. 
  
Death: all-cause mortality during anti-TB treatment. 
  
Lost-to-follow up: a TB patient for whom treatment was 
interrupted for two consecutive months or more. It was previously 
termed as 'default.' 
  
Treatment after failure: patients who have previously been 
treated for TB and whose treatment failed at the end of their most 
recent course of treatment. 
  
Treatment after loss to follow up: patients who have previously 
been treated for TB and were declared lost-to-follow up at the end 
their most recent course of treatment. 
  
New patients: patients who have never been treated for TB or have 
taken anti-TB drugs for less than one month in the past. 
  
Statistical methods: data were analysed using STATA 14. Out of a 
total of 531 eligible participants, two records found to be missing data 
on duration of treatment and TB treatment history were dropped from 
the analyses. Three patients' HIV statuses were unknown and were 
excluded. The number of excluded observations added up to less than 
1% (5/531) of the total number of observations, hence it was 
assumed that data were missing completely at random. A complete 
case analysis of 526 observations was therefore conducted. 
Proportions and frequencies were calculated for binary or categorical 
variables. A modified Poisson regression analysis was used to 
measure the magnitude and strength of the association between HIV 
infection and TB treatment outcomes. TB treatment outcomes in this 
regard was categorized into a binary variable, namely successful 
outcome (cure or treatment complete) and Adverse Outcome (died, 
lost-to-follow up or treatment failure). Duration of survival was 
calculated from the date of initiation of TB treatment to the date of 
death, date patient discontinued treatment (as a result of LTFU) or 
date of treatment completion for patients who remained alive. The 
outcome of interest (event) was death in the survival analysis and 
patients who were event free (alive) or were lost-to-follow up were 
censored. Kaplan-Meier survival estimates was used to determine 
survival function and plot survival curves. A Log-rank test was carried 
out to test for equality of survivor functions between the two groups 
(HIV infected and HIV non-infected patients). All tests were two-tailed 
and statistical significance was set at 0.05. 
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Ethics approval: ethical approval was obtained from the Ghana 
Health Service Ethics Review Committee; reference number: GHS-
ERC: 35/12/2016 and the University of Florida Institutional Review 
Board; IRB number: IRB201701922. A full waiver of informed consent 
was granted since patients were not encountered directly in the study. 






Demographic characteristics and distribution of HIV 
infection among study participants: in Table 1, the distribution 
of demographic and clinical characteristics among HIV-positive and 
HIV-negative TB patients is shown. Patients within the ages of 40 to 
49 years had the highest proportion of HIV infections which was 
28.9% (37/128). Almost 30% (54/182) of females were HIV infected; 
nearly twice as much infections among males. Patients with smear-
negative pulmonary TB had 37.2% (45/121) HIV infections followed 
by those with extra-pulmonary TB - 24.2% (16/66) and smear-
positive TB which was 13.6% (46/339). Table 2 illustrates the 
treatment outcomes by demographic and clinical profiles. Age was 
almost equally distributed across all the four age groups; the lowest 
proportion being 23.6% among 15 to 29 years and the highest being 
27.8% among 50 years and over. About two-thirds of the participants 
were males (n = 344; 65.4%) and more than 60% of the participants 
were diagnosed with smear-positive TB. The overall prevalence of HIV 
among the participants was 20.3% (107/526) and nearly all (96%; 
505/526) the patients were treated as new TB patients. 
  
TB treatment outcomes: eighty-three out of 107 (77.6%) HIV-
positive individuals had successful treatment, compared to 91.2% 
(382/419) treatment success among HIV-negative individuals. 
Thirteen percent (19/146) of those aged 50 years and above died 
during treatment whilst deaths among 15 to 29 year-olds was 1.6% 
(2/124). The proportion of HIV-positive individuals who died was 
21.5% (23/107); about four times that of HIV-negative individuals - 
5.5% (23/419). In the modified Poisson regression analysis illustrated 
in Table 3, HIV status and history of TB treatment were both 
significant predictors of treatment outcomes in the unadjusted 
analysis. In the adjusted model, only HIV status remained significant. 
Being HIV infected increased the risk of adverse outcome relative to 
successful outcome by almost 3 times (2.89; 95% CI 1.76 to 4.74). 
The relative risk of adverse outcome (death/treatment failure/LTFU) 
compared to successful outcome (cure/treatment completed) among 
patients who were on retreatment was not significant after controlling 
for sex, age, type of TB, hospital and HIV status. The same is true for 
all the other variables that were added to the model. 
  
Time to deaths: forty-six deaths in total were recorded within the 
treatment period. Most of these deaths (n = 29; 63%) occurred within 
the first two months (intensive phase) of TB treatment as observed 
in Table 4. In Table 5, the highest mortality rates observed was 
among HIV-positive persons and persons 50 years and above; 38.6 
per 1000 person months and 22.6 per 1000 person months 
respectively. The rate of deaths among patients in the second hospital 
was more than twice that in the first hospital; 19.3 per 1000 person 





The probability of survival at the end of the analysis time among the 
total sample of patients in this study was 89.4%. Plotting the curves 
separately according to HIV status showed that those with HIV 
infection had a lower survival, confirming documented evidence that 
being HIV infection increases one's risk of mortality during TB 
treatment. Our finding of higher mortality in TB/HIV co-infected 
patients compared to those with TB only is similar to that reported 
among patients attending a chest clinic in a teaching hospital in 
Ghana, but in contrast, we did not find a difference in default rates 
between the two groups [20]. Again, in Sudan, a significantly higher 
case-fatality rate among persons with TB/HIV co-infection (12%) 
compared to those with TB infection only (1.8%) was found. HIV tests 
were conducted among patients in the study however, results were 
anonymised and not linked [13]. The proportion of LTFU and 
treatment failure which is less than 3% of the entire cohort 
corroborates with previous reports about TB treatment outcomes in 
other countries and in Ghana [11, 13]. The component of adverse 
outcome which was most influenced or affected by HIV infection was 
death. Interventions targeted towards reducing deaths among TB 
patients may help contribute to End TB Strategy goals and targets. 
The effect of the concurrent use of anti-TB treatment and ART could 
not be estimated in this study because only four (3.8%) were 
documented to have been given concurrent treatment and hence 
could not be included in the analyses. It is quite surprising to see that 
such a low proportion of HIV infected individuals in this study were 
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given concurrent ART. In a study in Nigeria, 16% out of 568 TB/HIV 
co-infected patients received concurrent treatment. Survival was 
lowest among those who were not on ART and their risk of mortality 
was aHR 1.39 (95 %CI 1.04 to 1.86) compared to those who were on 
ART [15]. The low uptake of ART in our study may have contributed 
to the high mortality among the HIV co-infected patients since several 
studies show that integrated therapy has significant survival 
benefit [21-23]. One retrospective study on the predictors of mortality 
among TB/HIV co-infected patients reported a significant increase in 
the risk of mortality (aHR = 3.15 95%CI 1.95 to 5.11) among patients 
who were not given cotrimoxazole preventive therapy during 
treatment. They also found that patients on antiretroviral therapy 
(ART) had a hazard ratio of 0.35 (95%CI 0.19 to 0.64) [24]. 
Agreeably, HIV patients in this study who were not started on 
cotrimoxazole preventive therapy during treatment had a hazard ratio 
of 4.18 (95%CI 1.71 to 10.21). This report is also consistent with that 
of a study conducted in Cameroun [25]. 
  
Additionally, according to two other studies, patients who do not take 
cotrimoxazole preventive therapy have an increased risk of death or 
adverse outcome [26, 27]. It is estimated that about 25% of TB/HIV 
co-infected people in Ghana receive concurrent treatment despite 
recommendations in the WHO guidelines for TB/HIV co-infection. ART 
should be initiated for all patients with TB/HIV co-infection regardless 
of their CD4 cell count. TB treatment should be started first, followed 
by ART as soon as possible and within the first eight weeks of starting 
TB treatment [19]. There is a need for qualitative studies to bring out 
the challenges or barriers to the implementation of the guidelines 
especially in the Ghanaian setting. Possible solutions to this problem 
may include training health professionals in concurrent management 
of TB and HIV or to develop optimal models to facilitate integration 
of TB and HIV services in health facilities. The difference in the 
mortality rates between the two hospitals in this study may have been 
due to institutional factors, patient-factors or both. The rate of death 
among the HIV-positive persons in this study was almost twice (38.6 
per 1000 person months) that found in an Ethiopian study where 
among TB/HIV co-infected patients, a rate of 20.6 per 1000 person 
months was recorded. However, the mortality rates among HIV non-
infected persons were similar in both studies; 10.8 per 1000 person 
months in the Ethiopian study and 9.1 per 1000 person months in our 
study [16]. Most studies report that majority of these deaths occur in 
the first few weeks of treatment [15, 28]. In our study, the 
proportionate mortality at the end of the first two weeks was 23.9% 
and 63.0% at the end of the first two months. A possible explanation 
to this observation is that those who die in the first few weeks of 
treatment report to the hospitals late. The causes of delay may be 
due to fear of drug toxicities, stigmatisation, self-medication, delay in 
diagnosis of TB and/or HIV infection and counselling among other 
others [8, 29]. 
  
Limitations of the study: missing data on variables such as weight 
and height made it impossible to test their associations with the 
outcomes. Also, information on CD4 cell counts, drug adherence, co-
morbidities and other socio demographic variables that could have 






HIV infection significantly increased the risk of death among the 
patients. More than 60% of deaths occurred in the first two months 
of TB treatment. Initiation of ART within eight weeks of starting anti-
TB treatment as recommended by WHO [28] may have averted some 
of these deaths. Measures should be put in place to improve ART 
coverage among persons with TB/HIV co-infection to help reduce 
mortality. 
  
What is known about this topic 
 HIV infection increases the risk of death among TB 
patients; 
 Administration of concurrent ART and anti-TB therapy 
reduces the risk of death among TB/HIV co-infected 
patients. 
What this study adds 
 The co-administration of ART and anti-TB therapy is 
suboptimal in some hospitals in the Accra metropolis; 
 Health system factors in some hospitals in the Accra 
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Table 1: distribution of demographic and clinical characteristics among HIV infected and HIV non-infected TB 
patients in two urban hospitals in the Accra Metropolis 




Hospital     
1st hospital 43 (19.1) 182 (80.9) 
2nd hospital 64 (21.3) 237 (78.7) 
Sex     
Male 53 (15.4) 291 (84.6) 
Female 54 (29.7) 128 (70.3) 
Age (years)     
15 – 29 9 (7.3) 115 (92.7) 
30 – 39 35 (27.3) 93 (72.7) 
40 – 49 37 (28.9) 91 (71.1) 
50+ 26 (17.8) 120 (82.2) 
TB type     
PTB positive 46 (13.6) 293 (86.4) 
PTB negative 45 (37.2) 76 (62.8) 
Extra pulmonary TB 16 (24.2) 50 (75.8) 
TB history     
New 103 (20.4) 401 (79.6) 
Relapse 2 (14.3) 12 (85.7) 
Treatment after failure 1 (16.7) 5 (83.3) 
Treatment after LTFU 0 (0) 1 (100.0) 
Treatment Outcome     
Cure 34 (31.8) 262 (62.5) 
Treatment complete 49 (45.8) 120 (28.6) 
Died 23 (21.5) 23 (5.5) 
Lost-to-follow up 0 (0.0) 10 (2.4) 
Treatment failed 1 (0.9) 4 (1.0) 
Co-trimoxazole preventive therapy     
Yes 94 (87.0) - 
No 14 (13.0) - 
Anti-retroviral therapy     
Yes 4 (3.7() - 
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Table 2: treatment outcomes by demographic and clinical profiles of TB patients 
    
Total 
N=526 (%) 








Age (years)         
15 – 29 124 (23.6) 116 (93.6) 2 (1.6) 6 (4.8) 
30 – 39 128 (24.3) 116 (90.6) 11 (8.6) 1 (0.8) 
40 – 49 128 (24.3) 110 (86.0) 14 (10.9) 4 (3.1) 
50+ 146 (27.8) 123 (84.3) 19 (13.0) 4 (2.7) 
Sex         
Male 344 (65.4) 304 (88.4) 30 (8.7) 10 (2.9) 
Female 182 (34.6) 161 (88.5) 16 (8.8) 5 (2.7) 
Hospital         
1st Hospital 225 (42.8) 201 (89.4) 12 (5.3) 12 (5.3) 
2nd Hospital 301 (57.2) 264 (87.7) 34 (11.3) 3 (1.0) 
TB type         
PTB + 339 (64.5) 297 (87.6) 30 (8.9) 12 (3.5) 
PTB – 121 (23.0) 107 (88.4) 12 (9.9) 2 (1.7) 
Extra Pulmonary TB 66 (12.5) 61 (92.4) 4 (6.1) 1 (1.5) 
Treatment history         
New 505 (96.0) 448 (88.7) 44 (8.7) 13 (2.6) 
Retreatment 21 (4.0) 17 (81.0) 2 (9.5) 2 (9.5) 
HIV status         
Positive 107 (20.3) 83 (77.6) 23 (21.5) 1 (0.9) 
Negative 419 (79.7) 382 (91.2) 23 (5.5) 14 (3.3) 




Table 3: modified poisson regression (with robust standard error) of factors associated with TB 
treatment outcome 
Predictor Unadjusted RR (95% CI) Adjusted RR (95% CI) 
Sex     
Female 1 1 
Male 1.00 (0.61 - 1.66) 1.16 (0.69 - 1.94) 
Age (years)     
15 - 29 1 1 
30 - 39 1.45 (0.61 - 3.44) 1.17 (0.50 - 2.72) 
40 - 49 2.17 (0.98 - 4.83) 1.64 (0.70 - 3.83) 
50 and over 2.44 (1.13 - 5.27) 2.26 (1.01 - 5.07) 
Type of TB     
Smear positive pulmonary 
TB 
1 1 
Smear negative pulmonary 
TB 
0.93 (0.53 - 1.65) 0.62 (0.34 -1.14) 
Extra-pulmonary TB 0.61 (0.25 - 1.48) 0.54 (0.23 - 1.27) 
TB treatment history     
New 1 1 
Retreatment 1.18 (3.08 - 4.51) 1.61 (0.62 - 4.19) 
Hospital     
1st Hospital 1 1 
2nd Hospital 1.15 (0.71 - 1.87) 1.22 (0.74 - 2.03) 
HIV status     
Negative 1 1 
Positive 2.54 (1.59 - 4.06) 2.89 (1.76 - 4.74) 
RR= Relative risk; TB treatment outcome= Successful outcome/ adverse outcome 
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Mortality rate per 100 pm 
(95% CI) 
Week 1 6 13.0 1.1 541.9.4 (243.5 - 1206.3) 
Week 2 5 10.9 2.7 186.7 (77.7 - 484.5) 
Week 3 3 6.5 3.1 95.5 (30.8 - 296.0) 
Week 4 4 8.7 3.7 107.7 (40.4 - 286.9) 
2nd month 11 23.9 19.8 55.7 (30.8 - 100.6) 
3rd month 6 13.0 17.4 34.4 (15.5 - 76.6) 
4th month 3 6.5 15.9 18.9 (6.1 - 58.5) 
5th month 3 6.5 82.2 3.6 (1.2 - 11.3) 
6th month+ 5 10.9 2982.4 0.2 (0.1 - 0.4) 











Mortality rate per 1000 pm 
(95% CI) 
Age (years)         
15 - 29 124 2 768.9 2.6 (0.6 - 10.4) 
30 - 39 128 11 762.1 14.4 (8.0 - 26.1) 
40 - 49 128 14 757.5 5.3 (10.9 - 31.2) 
50 and above 146 19 839.7 22.6 (14.4 - 35.5) 
Sex         
Male 344 30 2058.5 14.6 (10.2 - 20.8) 
Female 182 16 1069.8 14.9 (9.2 - 24.4) 
Type of TB         
Smear positive TB 339 30 1987.1 15.1 (10.5 - 21.6) 
Smear negative TB 121 12 680.1 17.6 (10.0 - 31.1) 
Extra-pulmonary TB 66 4 461.0 8.7 (3.3 - 23.1) 
TB treatment history         
New 505 44 2977.2 14.8 (11.0 - 19.9) 
   Retreatment 21 2 151.1 13.2 (3.3 - 52.9) 
HIV status         
Positive 107 23 596.0 38.6 (25.6 - 58.1) 
Negative 419 23 2532.3 9.1 (6.0 - 13.7) 
Hospital         
1st hospital 225 12 1370.4 8.8 (5.0 - 15.4) 
2nd hospital 301 34 1757.9 19.3 (13.8 - 27.1) 
Year         
2013 191 14 1165.7 12.0 (7.1 - 20.3) 
2014 156 14 905.9 15.5 (9.2 - 26.1) 
2015 179 18 1056.7 17.0 (10.7 - 27.0) 
pm = person months 
 
 
 
 
